脊髓脑膜瘤的临床、分子和遗传特征。

IF 3.7 Q1 CLINICAL NEUROLOGY Neuro-oncology advances Pub Date : 2024-08-31 eCollection Date: 2024-10-01 DOI:10.1093/noajnl/vdae123
Dylan Deska-Gauthier, Laureen D Hachem, Justin Z Wang, Alex P Landry, Leeor Yefet, Chloe Gui, Yosef Ellengbogen, Jetan Badhiwala, Gelareh Zadeh, Farshad Nassiri
{"title":"脊髓脑膜瘤的临床、分子和遗传特征。","authors":"Dylan Deska-Gauthier, Laureen D Hachem, Justin Z Wang, Alex P Landry, Leeor Yefet, Chloe Gui, Yosef Ellengbogen, Jetan Badhiwala, Gelareh Zadeh, Farshad Nassiri","doi":"10.1093/noajnl/vdae123","DOIUrl":null,"url":null,"abstract":"<p><p>Spinal meningiomas comprise 25%-46% of all primary spinal tumors. While the majority are benign and slow-growing, when left untreated, they can result in significant neurological decline. Emerging clinical, imaging, and molecular data have begun to reveal spinal meningiomas as distinct tumor subtypes compared to their intracranial counterparts. Moreover, recent studies indicate molecular and genetic subtype heterogeneity of spinal meningiomas both within and across the classically defined WHO grades. In the current review, we focus on recent advances highlighting the epidemiological, pathological, molecular/genetic, and clinical characteristics of spinal meningiomas. Furthermore, we explore patient and tumor-specific factors that predict prognosis and postoperative outcomes. We highlight areas that require further investigation, specifically efforts aimed at linking unique molecular, genetic, and imaging characteristics to distinct clinical presentations to better predict and manage patient outcomes.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485713/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical, molecular, and genetic features of spinal meningiomas.\",\"authors\":\"Dylan Deska-Gauthier, Laureen D Hachem, Justin Z Wang, Alex P Landry, Leeor Yefet, Chloe Gui, Yosef Ellengbogen, Jetan Badhiwala, Gelareh Zadeh, Farshad Nassiri\",\"doi\":\"10.1093/noajnl/vdae123\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Spinal meningiomas comprise 25%-46% of all primary spinal tumors. While the majority are benign and slow-growing, when left untreated, they can result in significant neurological decline. Emerging clinical, imaging, and molecular data have begun to reveal spinal meningiomas as distinct tumor subtypes compared to their intracranial counterparts. Moreover, recent studies indicate molecular and genetic subtype heterogeneity of spinal meningiomas both within and across the classically defined WHO grades. In the current review, we focus on recent advances highlighting the epidemiological, pathological, molecular/genetic, and clinical characteristics of spinal meningiomas. Furthermore, we explore patient and tumor-specific factors that predict prognosis and postoperative outcomes. We highlight areas that require further investigation, specifically efforts aimed at linking unique molecular, genetic, and imaging characteristics to distinct clinical presentations to better predict and manage patient outcomes.</p>\",\"PeriodicalId\":94157,\"journal\":{\"name\":\"Neuro-oncology advances\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485713/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/noajnl/vdae123\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

脊髓脑膜瘤占所有原发性脊髓肿瘤的 25%-46%。虽然大多数脊髓脑膜瘤是良性的,生长缓慢,但如果不及时治疗,就会导致神经功能严重衰退。新出现的临床、成像和分子数据已开始揭示脊髓脑膜瘤与其颅内同类肿瘤相比具有不同的肿瘤亚型。此外,最近的研究表明,脊髓脑膜瘤的分子和遗传亚型在WHO经典定义的分级内和分级间都存在异质性。在本综述中,我们重点介绍了脊髓脑膜瘤在流行病学、病理学、分子/遗传学和临床特征方面的最新进展。此外,我们还探讨了预测预后和术后效果的患者和肿瘤特异性因素。我们强调了需要进一步研究的领域,特别是将独特的分子、遗传和成像特征与不同的临床表现联系起来,以便更好地预测和管理患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical, molecular, and genetic features of spinal meningiomas.

Spinal meningiomas comprise 25%-46% of all primary spinal tumors. While the majority are benign and slow-growing, when left untreated, they can result in significant neurological decline. Emerging clinical, imaging, and molecular data have begun to reveal spinal meningiomas as distinct tumor subtypes compared to their intracranial counterparts. Moreover, recent studies indicate molecular and genetic subtype heterogeneity of spinal meningiomas both within and across the classically defined WHO grades. In the current review, we focus on recent advances highlighting the epidemiological, pathological, molecular/genetic, and clinical characteristics of spinal meningiomas. Furthermore, we explore patient and tumor-specific factors that predict prognosis and postoperative outcomes. We highlight areas that require further investigation, specifically efforts aimed at linking unique molecular, genetic, and imaging characteristics to distinct clinical presentations to better predict and manage patient outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
International symposium on inheritable central nervous system (CNS) cancer predisposition: A prologue. Correction to: Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria. Effect of antibiotic drug use on outcome and therapy-related toxicity in patients with glioblastoma-A retrospective cohort study. Empowering the next generation in neuro-oncology: Introduction of the EANO Career Boost Initiative. A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1